pivalyloxymethyl butyrate has been researched along with Leukemia, Lymphocytic, Chronic, B-Cell in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aviram, A; Bairey, O; Ben-Dror, I; Rabizadeh, E; Shaklai, M; Zimra, Y | 1 |
1 other study(ies) available for pivalyloxymethyl butyrate and Leukemia, Lymphocytic, Chronic, B-Cell
| Article | Year |
|---|---|
Doxorubicin and a butyric acid derivative effectively reduce levels of BCL-2 protein in the cells of chronic lymphocytic leukemia patient.
Topics: Antineoplastic Combined Chemotherapy Protocols; bcl-2-Associated X Protein; Butyrates; Cell Survival; Dose-Response Relationship, Drug; Doxorubicin; Flow Cytometry; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured | 2001 |